To evaluate risk factors for recurrent events in patients enrolled in the SteFlux ( Superficial Thromboembolism Fluxum ) clinical trial which compared different doses and duration of low molecular weight heparin ( parnaparin ) for superficial vein thrombosis ( SVT ) .